Innova Captab

84
🚨 STOCK TO WATCH 🚨

₹1,050–₹1,060 → ₹1,374 → ₹1,530 → ₹3,113 👀

A fast-growing integrated pharmaceutical player appearing on my Weekly R4 Breakout Scanner.

Innova Captab Ltd.

📌 Buy Zone: ₹1,050–₹1,060
📌 Breakout Zone: ₹1,060
🛑 Stop Loss: ₹710
🎯 Target 1: ₹1,374
🎯 Target 2: ₹1,530
🎯 Target 3: ₹3,113

Why Innova Captab?

💊 Integrated pharma platform: The company operates across CDMO and Branded Generics, covering research, development, manufacturing and market-facing pharma operations.

🌍 Strong CDMO franchise: CDMO revenue reached ₹1,133.35 Cr in FY26, growing 23.8% YoY, with 350+ customers across 60+ countries.

📈 Branded Generics acceleration: FY26 Branded Generics revenue reached ₹496.67 Cr, representing 51.4% YoY growth.

🏭 Capacity expansion: The company has manufacturing facilities across Baddi, Dehradun, Taloja and Kathua, with further investment in manufacturing and R&D capabilities.

🌐 Export opportunity: Exports contributed 31.3% of FY26 revenue, with presence across 60+ countries and growing access to regulated markets.

📊 Weekly Camarilla R4 Breakout Setup

Why It Caught My Attention

✅ Strong CDMO growth
✅ 51%+ Branded Generics growth
✅ 350+ global customers
✅ Expanding manufacturing capacity
✅ Growing international exposure
✅ Weekly R4 Momentum Breakout

⚠️ High Risk – High Reward Setup. Always follow strict stop-loss and disciplined position sizing.

📢 Disclaimer: This content is for educational purposes only and not investment advice. Please do your own due diligence before making any investment decisions.

Risk Defined. Reward Visible.

© 20K Microcap Investing | R4 Momentum Desk

#InnovaCaptab #PharmaStocks #CDMO #Pharmaceuticals #PharmaIndia #HealthcareStocks #StockMarketIndia #IndianStocks #StocksToWatch #R4Breakout #MomentumInvesting #20KMicrocap

Disclaimer

The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.